STEM CELLS MARKET ANALYSIS

Market News

Global Stem Cells Market : Key Developments

•  On February 13, 2023, STEMBIOSYS, INC., a U.S.-based company that focuses on stem cell research, announced the launch of NeuroMatrix, an astrocyte-derived extracellular matrix that enables the culture of human induced pluripotent stem cell (hiPSC)-derived and primary neural cell types. STEMBIOSYS INC. designed NeuroMatrix to expand the use of iPSC-derived neurons in drug discovery and toxicity testing.
• On April 17, 2023, Gamida Cell, a cell therapy company working to turn cells into powerful therapeutics, announced that the U.S. Food and Drug Administration (FDA) had approved Gamida Cell’s allogeneic cell therapy, Omisirge (omidubicel-onlv), for use in adult and pediatric patients 12 years of age and older with hematologic malignancies. The therapy is planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection. Omisirge allogeneic stem cell transplant therapy was approved on the basis of a global, randomized Phase 3 clinical study.

Global Stem Cells Market: Key Trends

• Key market players are adopting inorganic strategies like mergers, collaborations, and partnership agreements to help propel the growth of the global stem cells market over the forecast period. On June 13, 2023, STEMBIOSYS, INC. announced the launch of CELLvo Atrial Cardiomyocyte, a chamber-specific human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) designed to function identically to human atrial cardiomyocytes.
• The establishment of new companies aimed at curing various diseases and disorders will help propel the growth of the stem cells market over the forecast period. In November 2022, Therapeutic Solutions International, Inc., a company focused on immune modulation for the treatment of several specific diseases, established a company called Breathe Biologics, which will aim to cure Chronic Obstructive Pulmonary Disease (COPD).